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Enhanced tumor-targeted gene delivery by
bioreducible polyethylenimine tethering EGFR
divalent ligands†
Duhwan Lee,‡a Yeong Mi Lee,‡a Jihoon Kim,a Myung Kyu Leeb and Won Jong Kim*a
This work demonstrates successful delivery of a gene to EGFR-overexpressed cancer cells by using a
rationally designed branched GE11 peptide as a targeting ligand. In addition, we exploited the eﬀect of the
divalent structure of the branched GE11 peptide on the gene delivery and tumor targeting eﬃciency,
compared to the monovalent GE11 peptide. The GE11 or branched GE11-tethered polymers were suc-
cessfully synthesized. They are composed of a targeting peptide, disulﬁde crosslinked low molecular
weight polyethylenimine and polyethylene glycol. Here, we evaluated the physicochemical properties,
cytotoxicity and in vitro transfection eﬃciency and in vivo biodistribution of the GE11 and branched GE11
tethered polyplexes. Our results demonstrated that GE11 and bGE11-tethered gene delivery carriers
showed eﬃcient gene condensing ability, an enhanced transfection eﬃciency and targeting ability with
low cytotoxicity. Interestingly, the branched GE11-tethered polymer showed the greater targeting ability
to EGFR-overexpressed cancer cells in vivo than the GE11-tethered polymer. Therefore, this branched
structure of targeting ligand has the potential for providing a novel strategy to design an eﬃcient targeted
delivery system.
Introduction
For an eﬃcient polymeric delivery system, it is essential to pre-
cisely deliver the gene/polymer complex (polyplex) or drug into
a targeted tissue or organ. To solve this issue, researchers have
developed numerous targeting ligands which can bind to the
specific receptor overexpressed on the target tissues or
organs.1–3 Enhanced targeted delivery of payloads has been
attained by using a combination of ligands and receptors;
folate/folate receptor, RGD peptide/integrin αvβ5, NGR peptide/
aminopeptidase N receptor and epidermal growth factor
(EGF)/EGF receptor (EGFR).4–7 Among them, EGFR has been
considered as one of the promising targets for gene and drug
delivery systems because of its overexpression in lung, liver,
head and neck cancers and a wide spectrum of human cancers
from epithelial origin.8,9 Researchers have shown enhanced
targeting and delivery eﬃciency of therapeutic genes or drugs
by tethering EGF to polymers, carbon nanotubes, liposomes,
and dendrimers.10–13 However, EGF itself is at risk of activating
the EGFR, which leads to cell proliferation and reduces the
antitumor eﬀect of a therapeutic gene or drug.14 The GE11
peptide (YHWYGYTPQNVI), found by phage display library to
be a substitute for EGF, binds to the receptor and has low
mitogenic activity.15
The structure of targeting ligands is an important issue in
developing targeted delivery systems.16–18 For example, the
cyclic form of NGR and RGD has shown better binding aﬃnity
to each respective receptor than the linear form because
restriction of the structures enhances the receptor-ligand inter-
actions by stabilizing the bent conformation of the
peptide.19,20 In addition, multivalent interactions between
ligand and target molecules are widely utilized in biological
processes, such as in the adhesion of a virus to the surface of a
cell, binding of transcription factors to multiple sites on DNA,
and recognition of antigens by antibodies.21–24 These multi-
valent interactions are generally much stronger than mono-
valent interactions.21 However, a delivery system utilizing a
multivalent form of targeting ligand has yet to be evaluated.
Therefore, we used two types of targeting peptides which
are structurally diﬀerent. One is the GE11 peptide itself, and
the other is branched GE11 (bGE11) which has two ligands in
one peptide.
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Recently, we reported an eﬃcient gene delivery system com-
posed of bioreducible branched polyethylenimine (BPEI-SS),
polyethylene glycol (PEG) and targeting peptide.25–27 Branched
polyethylenimine (BPEI), which is the representative cationic
polymer for gene delivery, exhibits molecular weight (MW)
dependency in transfection eﬃciency and cytotoxicity. It has
been reported that BPEI with a high MW (>25 kDa) shows a
high transfection eﬃciency and low biocompatibility, while
BPEI with a low MW (<1.8 kDa) shows a low transfection
eﬃciency and low cytotoxicity.28 The shortcomings of BPEI can
be overcome by introducing the disulfide linkage to the low
MW BPEI. BPEI-SS shows a high transfection eﬃciency as it is
able to form a stable polyplex with pDNA in the extracellular
compartments. Subsequently, BPEI-SS is degraded in reductive
conditions in intracellular compartments and shows low cyto-
toxicity.29 In addition, the conjugation of a PEG moiety pro-
vides stability in blood and biocompatibility for the polyplex
in vitro and in vivo.
In this study, we introduced two structurally diﬀerent
EGFR-targeting peptides to BPEI-SS-PEG and evaluated their
physicochemical properties, in vitro transfection eﬃciency,




BPEI with MW 25 000 Da (BPEI25k), propylene sulfide and
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) were purchased from Sigma-Aldrich (St. Louis, MO,
USA). BPEI with MW 1200 Da (BPEI1.2k) was obtained from
Polyscience, Inc. (Warrington, PA, USA). Methanol, diethyl
ether and dimethyl sulfoxide (DMSO) were purchased from
Samchun pure chemical (Pyeongtaek, Korea). A dialysis mem-
brane with a molecular weight cut-oﬀ (MWCO) of 10 kDa was
purchased from Spectrum Laboratories (Rancho Domingues,
CA, USA). YOYO-1 iodide was obtained from Invitrogen
(Eugene, OR, USA). Mounting medium for fluorescence with
DAPI was purchased from VECTOR (Berlingame, CA, USA) and
Cy5.5 NHS ester was obtained from GE healthcare (Little Chal-
front, UK). Heterobifunctional polyethylene glycol with MW
5000 Da (α-maleimide-PEG-ω-N-hydroxysuccinimide ester poly-
ethylene glycol, MAL-PEG-NHS) was purchased from NOF Cor-
poration (White Plains, NY, USA). GE11 peptide and branched
GE11 (bGE11) peptide were prepared by solid phase peptide
synthesis (GE11 = YHWYGYTPQNVIGRC and bGE11 = (YHWY-
GYTPQNVI-GG)2-KGRC). Agarose powder and Tris-acetate-
EDTA (TEA) buﬀer were purchased from bioneer Corp.
(Daejeon, Korea). Dulbecco Modified Eagle’s medium (DMEM)
and Roswell Park Memorial Institute medium (RPMI 1640),
penicillin-streptomycin, fetal bovine serum (FBS) and Dulbec-
co’s phosphate buﬀered saline (DPBS) were obtained from
Corning (Manassas, VA, USA). A luciferase assay system with
reporter lysis buﬀer was purchased from Promega (Madison,
WI, USA). Bradford protein assay reagent was purchased from
Pierce Chemical Co. (Rockford, IL, USA). A549, Huh-7 and
NIH3T3 cell lines were obtained from the Seoul National Uni-
versity Cell Bank (Seoul, Korea).
Purification of pDNA
Plasmids (pDNA) encoding luciferase were propagated in a
chemically competent DH5α strain (GibcoBRL, Rockville, MD,
USA) and prepared with a GeneJET Plasmid Maxiprep Kit
(Thermo scientific, Waltham, MA, USA). The concentration of
pDNA was determined by measuring absorbance at 260 nm,
and we found the optical density at 260 to 280 nm to be in the
range 1.8–1.9.
Synthesis of bioreducible branched polyethylenimine
(BPEI-SS)
BPEI-SS was synthesized by previously reported methods with
some modification.29 Briefly, BPEI1.2k (1 g) in 20 mL vials was
dissolved in 10 mL deionized water (DW) and the pH of the
solution was adjusted to 7.2 by adding 1 M HCl. The solution
was lyophilized for 2 days. The resultant solid was dissolved in
methanol and the solution was purged with nitrogen for
15 min. Propylene sulfide (7 eq.) was added using a syringe,
then the reaction mixture was stirred at 60 °C for 24 h. The
product was purified by precipitation in cold diethyl ether
twice, and the degree of thiolation was measured using 1H
NMR in D2O (Bruker 300 MHz). To synthesize BPEI-SS,
BPEI-SH was dissolved in DMSO and oxidative crosslinking
was performed by stirring the solution at room temperature
for 48 h. Finally, the product was obtained by dialysis (MWCO
10 kDa) against DW and following lyophilization.
Fig. 1 Schematic diagram of gene delivery by using EGFR targeted
bioreducible polyethylenimine.
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Synthesis of peptide-tethered bioreducible BPEI
(BPEI-SS-PEG-GE11 and BPEI-SS-PEG-bGE11)
MAL-PEG-NHS (1 eq.) and GE11 or bGE11 peptides (1.2 eq. to
maleimide groups) were dissolved in anhydrous DMSO and
stirred at room temperature for 4 h. Next, BPEI-SS (19 eq. to
NHS group) dissolved in DMSO was added to the solution. The
reaction mixture was stirred at room temperature for 48 h.
Finally, the product was obtained by dialysis (MWCO 10 kDa)
against DW and following lyophilization. The chemical struc-
ture of BPEI-SS-PEG-GE11 (or bGE11) was analyzed by 1H NMR
in D2O. The conjugation ratio of peptide to polymer was deter-
mined by fluorescence spectrometry (Shimadzu, Japan). Free
peptide was used to draw a calibration curve for fluorescence
intensity at known concentration. As a control, PEG-conjugated
BPEI-SS (BPEI-SS-PEG) without targeting peptide was syn-
thesized by using para-nitrophenylchloroformate (pNPC)-acti-
vated methoxy PEG.
Preparation of polyplex
Polyplexes (polymer/pDNA complex) with 1 ≤ N/P ≤ 15, (where
N is the molar amount of nitrogen in the polycation and P is
the molar amount of phosphate in the pDNA) were prepared
by adding polymer solution to the pDNA solution in PBS
buﬀer. The polyplexes were incubated at room temperature for
30 min.
Agarose gel retardation assay
Polyplexes with various N/P ratios were loaded onto a 1% (w/v)
agarose gel containing ethidium bromide (EtBr, 0.5 μg mL−1)
with a 6× loading dye. Electrophoresis was conducted at a con-
stant voltage of 100 V for 20 min in 0.5× TAE buﬀer (Tris-
acetate-EDTA). Naked pDNA (200 ng in 10 μL) was used as a
control. The gel was analyzed on a UV illuminator to observe
the position of the complexed pDNA relative to that of the
naked pDNA.
Size and zeta potential measurements
The polyplexes were prepared at various N/P ratios and diluted
using PBS buﬀer (pH 7.4, 140 mM NaCl). The final pDNA con-
centration was adjusted to 3 μg mL−1. The particle size and
zeta potential of each polyplex were measured by using a Zeta-
sizer Nano S90 and Z (Malvern Instruments, Malvern, U.K.),
respectively.
Cell culture
The EGFR-overexpressed (EGFR-positive) adenocarcinomic
human alveolar basal epithelial cell line (A549) and human
hepato cellular carcinoma cell line (Huh-7) were cultured in
RPMI164 medium and the EGFR-negative mouse embryo fibro-
blast (NIH3T3) cell line was cultured in DMEM medium. Both
mediums contain 10% FBS and 1% antibiotics and the cells
were grown and maintained in a humidified atmosphere with
5% CO2 at 37 °C.
MTT assay
The cytotoxicity of the polyplexes was evaluated by the stan-
dard MTT assay protocol. Briefly, cells were seeded onto 96-
well plates at a density of 5 × 103 cells per well and incubated
for 24 h. pDNA (0.1 μg μL−1) was complexed with the polymer
at predetermined N/P ratios in PBS. Cells were incubated with
polyplex in 100 μL of serum free media for 4 h, then incubated
for 20 h in 200 μL of fresh media containing 10% FBS. Next,
the media was replaced with 200 μL of fresh media and 20 μL
of 5 mg mL−1 MTT solution was added. After 4 h, the media
was removed and 200 μL of DMSO was added to each well to
dissolve the internalized purple formazan crystals. An aliquot
of 100 μL was taken from each well and transferred to a fresh
96-well plate. The absorption was measured at 570 nm using a
microplate spectrofluorometer (VICTOR3 V Multilabel
Counter, Perkin-Elmer-Wellesley, MA, USA). The control cells
which were not exposed to the transfection system were used
to represent 100% cell viability. The results are presented as a
mean and standard deviation (n = 3).
Luciferase reporter gene assay
Cells were seeded on 24-well plates at an initial density of 6 ×
104 cells per well and were incubated for 24 h in 500 μL of
media containing 10% FBS at 37 °C in a humidified atmos-
phere with 5% CO2. pDNA (0.1 μg μL−1) was complexed with
the polymer at predetermined N/P ratios in PBS. The cells were
incubated with the polyplex in 250 μL of serum-free media for
4 h, then incubated for 20 h in 500 μL of media containing
10% FBS. The cells were washed twice with 500 μL of PBS and
lysed by adding 200 μL of lysis buﬀer. Luciferase gene
expression was measured by using a microplate spcetrofluo-
rometer and a luciferase assay system. The results are pre-
sented as a mean and standard deviation (n = 3).
Flow cytometry
Cells were seeded in 12-well plates at a density of 1 × 105 cells
per well and incubated for 24 h. pDNA was labeled with
YOYO-1 iodide for 12 h before use. YOYO-labeled pDNA (0.1 μg
μL−1) was complexed with the polymer at a N/P ratio of 10 in
PBS buﬀer and incubated for 30 min. The cells were incubated
with polyplex for 4 h in serum-free media. After incubation,
the cells were washed twice with PBS and then trypsinized.
The harvested cells were centrifuged and the supernatant was
removed, then the cells were fixed with 4% paraformaldehyde
solution at 4 °C overnight. The paraformaldehyde solution was
removed by centrifugation, then the cells were resuspended in
PBS. The cells were analyzed using a FACS Caliber (Becton
Dickinson, San Jose, CA, USA) and Becton Dickinson Cell
Quest Software following the manufacturers’ protocol.
In vivo imaging
The POSTECH Biotech Center Ethics Committee approved all
of the animal experiments in this study. In vivo near-infrared
(NIR) imaging was performed using an IVIS spectrum small-
animal in vivo imaging system (Caliper Life Science) located at
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the Pohang Center of Evaluation of Biomaterials (Pohang Tech-
nopark). We evaluated the fluorescence intensity of the poly-
plexes labeled with Cy5.5 at an N/P ratio of 10 by using a Cy5.5
(ex = 675 nm, em = 740 nm) filter set. To investigate the target-
ing eﬃciency of GE11- and bGE11-conjugated and non-conju-
gated polyplexes, A549 cells were injected subcutaneously into
the right flank of female BALB/c-nu/nu mice. After 4 weeks,
the Cy5.5 labeled polyplexes (N/P = 20, 10 μg of pDNA) were
injected into mice via the tail vein. The mice were anesthetized
with 2–3% isoflurane and placed into the IVIS Spectrum
system. Images were taken 4 h after injection. 24 h after injec-
tion the A549 xenografted mice were sacrificed for ex vivo
imaging, and their major organs were collected. Each organ
was rinsed with PBS three times, mounted on a board, and
fluorescence images were taken using the IVIS Spectrum
system.
Results and discussion
Synthesis and characterization of bioreducible polymers with
targeting ligands
Prior to synthesizing the bioreducible BPEI with targeting
ligands, we firstly synthesized thiolated BPEI (BPEI-SH) by
using propylene sulfide as a thiolation agent at 7 equiv. to low
MW BPEI1.2k (Fig. S1†). Thiolation of BPEI was conducted by
the ring opening reaction between propylene sulfide and a
primary amine or secondary amine of BPEI. It was reported
that during the thiolation reaction, the buﬀering capacity of
BPEI was not changed significantly because primary and sec-
ondary amine groups are converted to higher order amines.29
Therefore, the endosomal escaping ability of BPEI is retained
after thiolation. After purification of BPEI-SH by precipitation
in diethyl ether, a sticky yellow product was obtained. The
degree of thiolation was determined using 1H NMR (Fig. S2†)
and the conjugation ratio was calculated as 5.32 (Table 1). The
disulfide crosslinked BPEI (BPEI-SS) was synthesized through
the oxidization of BPEI-SH with DMSO. After purification by
dialysis (MWCO = 10 kDa) against deionized water (DW) and
lyophilization by freezing drying, we could acquire a yellow
solid, the BPEI-SS. The MW of BPEI1.2k and BPEI-SS was eval-
uated using gel permeation chromatography (GPC). By con-
firming that peaks of BPEI-SS appeared at earlier retention
times compared to native BPEI1.2k, we could conclude that
the synthesized BPEI-SS has a higher average MW than
BPEI1.2k (Fig. S3†).
In order to introduce GE11 and bGE11 peptides to BPEI-SS,
each type of GE11 peptide was firstly conjugated to the hetero-
bifunctional polyethylene glycol (MAL-PEG-NHS). In each
peptide, there is a free thiol group in a cysteine residue at the
end of the peptide sequence. This free thiol group can react
with maleimide of MAL-PEG-NHS by Michael reaction. BPEI-S-
S-PEG-GE11 (or bGE11) was synthesized via the coupling reac-
tion between NHS in the resultant peptide-PEG-NHS and the
primary amine in BPEI-SS. After dialysis (MWCO = 10 kDa)
against DW and lyophilization, a slightly yellow sponge-like
powder was obtained. Successful conjugation between BPEI
and PEG was confirmed by 1H NMR (Fig. S2†). In the 1H NMR
spectra, protons in BPEI and the PEG main chains were found
at δ 2.6–3.1 and δ 3.6. Using the relative integral values of the
respective peaks in the 1H NMR spectra, it was confirmed that
the molar ratio of PEG to BPEI was 0.16, 0.12 and 0.12 for
BPEI-SS-PEG, BPEI-SS-PEG-GE11 and BPEI-SS-PEG-bGE11,
respectively. Each conjugated peptide was quantified by
measuring the fluorescence spectrometry. In the sequence of
the peptides there are several aromatic amino acids such as
tryptophan and tyrosine which can emit intrinsic fluorescence
(excitation: 280 nm, emission: 350 nm).30 Comparing the
measured fluorescence intensity of GE11 or bGE11-tethered
polymers with a calibration curve established by a predeter-
mined concentration of free peptide (Fig. S4†), the molar ratio
of peptide to BPEI1.2k was estimated to be 0.26 and 0.11 for
BPEI-SS-PEG-GE11 and BPEI-SS-PEG-bGE11, respectively.
Physicochemical properties of polyplex
Cationic polymers can interact with negatively charged
plasmid DNA (pDNA) through electrostatic interactions. The
resultant polyplex protects the gene from enzymes in the blood
flow as well as facilitates the cellular uptake of the gene by con-
densing the pDNA with micro-size to the nano scale. Therefore
for successful gene delivery it is essential to demonstrate
whether or not the synthesized polymer can condense genes
eﬀectively. After preparation of each polyplex at the various N/P
ratios, the pDNA condensing ability of the polymers was evalu-
ated by performing an agarose gel retardation assay. BPEI25k
was used as a positive control. As shown in Fig. 2A, while
BPEI25k could retard pDNA completely at N/P > 1, BPEI-S-
S-PEG and BPEI-SS-PEG-GE11 (or bGE11) could retard pDNA
completely at N/P > 10 and N/P > 5, respectively. The lower
pDNA condensing ability of PEG-decorated polymers com-
pared with BPEI25k could be attributed to the hindrance of
the PEG chain to the interaction between BPEI and the
pDNA.31 These results indicate that BPEI-SS-PEG-GE11 (or
bGE11) could successfully form the complex with pDNA.
The particle size and surface charge of the polyplexes also
aﬀect the uptake and transfection in vitro and in vivo. To
measure the size of the nanoparticles, polyplexes with various
N/P ratios were analyzed by using dynamic light scattering
(DLS). As shown in Fig. 2A, the particle size of all polyplexes
decreased as the N/P ratios increased because of the high
Table 1 Characterization of BPEI-SS-PEG and BPEI-SS-PEG-peptide
polymers
Denotation Thiola PEGb Peptidec
BPEI-SS-PEG 5.32 0.16 —
BPEI-SS-PEG-GE11 0.12 0.26
BPEI-SS-PEG-bGE11 0.12 0.11
aMeasured by 1H NMR. Molar ratio of thiol groups to BPEI1.2k chain
in polymers. bConfirmed by 1H NMR. Molar ratio of PEG to BPEI1.2k.
c Confirmed by fluorescence spectrometry. Molar ratio of GE11 or
bGE11 peptide to BPEI1.2k.
Biomaterials Science Paper























































































electrostatic interaction caused by the increased cationic
charge. The size of BPEI-SS-PEG/pDNA and BPEI-SS-PEG-GE11/
pDNA (or bGE11) changed to around 200 nm at a N/P ratio of
20 and 5, respectively, while these are above 2000 nm and
500 nm at a N/P ratio of 1. These results indicate that all poly-
mers at each proper N/P ratio could form the condensed nano-
complex with pDNA.
Positively charged polyplexes have the ability to adhere to
the negatively charged plasma membrane of cells through elec-
trostatic interactions. Therefore, it has been reported that posi-
tively charged polyplexes could be internalized by the cell
eﬀectively.32 As shown in Fig. 2B, the zeta potential increased
with the increase in the N/P ratio. In the case of BPEI-SS-PEG,
the polyplex showed a negative zeta potential at N/P < 10, while
it was positive at a N/P ratio of 20. In addition, BPEI-S-
S-PEG-GE11/pDNA (or bGE11) at a N/P ratio of 5 showed a
slightly positive zeta potential (±5 mV).
In summary, the results of the agarose gel retardation, DLS
and zeta potential measurements are correlated with each
other and demonstrate that the BPEI-SS-PEG-GE11 (or bGE11)
polyplex has suitable properties for in vitro and in vivo gene
delivery.
Cytotoxicity
It is well-known that BPEI with a high MW displays toxicity to
cells because the positively charged BPEI destabilizes the
plasma membrane or interacts with cellular components,
especially the membrane of mitochondria.33 To surmount
these problems, a disulfide linkage and PEG chains were
introduced to the low MW form of BPEI. The cytotoxicity of
BPEI-SS-PEG-GE11 (or bGE11) polyplexes was evaluated by
MTT assay using EGFR-positive A549 and Huh-7 cells and the
EGFR-negative NIH3T3 cell line (Fig. 3). Naked pDNA and
BPEI25k polyplexes at a N/P ratio of 10 as a gold standard
were used as the control. The BPEI25k polyplex showed signifi-
cant toxicity to all cell lines. However, no significant cytotox-
icity was observed for pDNA, BPEI-SS-PEG, BPEI-SS-PEG-GE11
and BPEI-SS-PEG-bGE11 polyplexes regardless of the EGFR
Fig. 2 Physicochemical properties of the polyplexes. (A) Size and
(B) zeta potential measurements, and (C) agarose gel retardation
assays of polyplexes of BPEI25k, BPEI-SS-PEG, BPEI-SS-PEG-GE11, and
BPEI-SS-PEG-bGE11 at various N/P ratios. The data represent the mean ±
SD (n = 3).
Fig. 3 Cell viability. EGFR-positive (A) A549 and (B) Huh-7 cell lines and
the EGFR-negative (C) NIH3T3 cell line were treated with pDNA (black),
BPEI25k (gray) at a N/P ratio 10, and BPEI-SS-PEG (red), BPEI-S-
S-PEG-GE11 (green) and BPEI-SS-PEG-bGE11 (blue) at various N/P
ratios. The data represent mean ± SD (n = 5; **P < 0.01, ***P < 0.001).
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receptor expression profile of the cells. These results could
be attributed to the degradation ability of BPEI and the
outside exposure of PEG. BPEI-SS, which is dissociated from
the polyplex, may be degraded into low MW BPEI with low
cytotoxicity in the reductive conditions of the cytoplasm. In
addition, BPEI and pDNA probably occupy the inner part of
the polyplex and the PEG chain may be located at the outer
part of the polyplex. Therefore, the PEG could hamper the
interaction between positively-charged BPEI and the nega-
tively-charged plasma membrane. These results confirmed
the biocompatibility of the GE11- and bGE11-conjugated
polymers.
In vitro transfection eﬃciency
The in vitro gene transfection potential of the EGFR-targeted
bioreducible polymers was investigated in EGFR-positive A549
and Huh-7 cell lines and the EGFR-negative NIH3T3 cell line
(Fig. 4). Cells treated with naked pDNA and BPEI-SS-PEG poly-
plexes were used as controls. The pDNA showed a negligible
transfection eﬃciency because cells do not internalize it with
ease. BPEI25k exhibited the most eﬀective transfection
eﬃciency with high cytotoxicity owing to the high density of
positive charge (Fig. 3 and 4). As the N/P ratio increased, the
transfection eﬃciency of the polymers increased for all cell
lines. In the EGFR-positive A549 and Huh-7 cell lines, GE11
and bGE11 tethered BPEI-SS polyplexes showed enhanced
transfection eﬃciency compared to the non-targeted BPEI-S-
S-PEG polyplex at all N/P ratios. However, in the EGFR-negative
NIH3T3 cell line, the non-targeted BPEI-SS-PEG polyplex
showed a much higher transfection eﬃciency than the GE11
or bGE11 tethered BPEI-SS polyplexes. These results demon-
strated that GE11- or bGE11-conjugated gene carriers have a
higher aﬃnity to EGFR-overexpressed cells than normal cells.
Interestingly, BPEI-SS-PEG-bGE11 which has a branched
peptide could deliver pDNA eﬀectively to the target cells com-
pared to BPEI-SS-PEG-GE11. These results can be explained by
the hypothesis of EGFR dimerization.34 It has been supposed
that proper EGFR dimerization seems to be necessary for
EGFR internalization. Applying this hypothesis, the branched
structure of bGE11 having two adjacent ligands can form a
divalent interaction with EGFR, which facilitates the enhanced
dimerization of the EGFR and receptor-mediated endocytosis,
compared to GE11. Although the dimerization of EGFR was
not directly confirmed, it could be concluded that the bGE11
tethered polyplex has a high transfection eﬃciency to EGFR-
overexpressed cancer cells.
Investigation of the interaction between polyplex and plasma
membrane
We hypothesized that the bGE11 tethered polyplex has more
chance to interact with EGFR, enhancing traﬃcking of the
polyplex into the cell. In order to confirm the strong inter-
action between the bGE11 tethered polyplexes and EGFR, we
carried out fluorescence-activated cell sorting analysis (FACS)
(Fig. 5). pDNA was labeled with YOYO-1 iodide before com-
plexation with the polymers. BPEI-SS-PEG, BPEI-SS-PEG-GE11
and BPEI-SS-PEG-bGE11 polyplexes at a N/P ratio of 10 were
transfected into EGFR-positive A549 and Huh-7 cell lines and
the EGFR-negative NIH3T3 cell line. Non-treated cells were
used as controls. In EGFR-positive A549 and Huh-7 cell lines,
the GE11 and bGE11 tethered BPEI-SS polyplexes showed
an enhanced interaction with the plasma membrane com-
pared to the non-targeted polyplex due to the interaction
between overexpressed EGFR and the peptides. Especially, the
BPEI-SS-PEG-bGE11 polyplex showed a higher interaction with
Fig. 4 In vitro transfection eﬃciency. EGFR-positive (A) A549 and (B)
Huh-7 cell lines and the EGFR-negative (C) NIH3T3 cell line were treated
with pDNA (black), BPEI25k (gray), BPEI-SS-PEG (red), BPEI-
SS-PEG-GE11 (green) and BPEI-SS-PEG-bGE11 (blue) at N/P ratios of
5, 10, and 15. The data represent the mean ± SD (n = 3; **P < 0.01,
***P < 0.001).
Biomaterials Science Paper























































































EGFR-positive cells than the BPEI-SS-PEG-GE11 polyplex.
However, in the EGFR-negative NIH3T3 cell line, non-targeted
BPEI-SS-PEG polyplex demonstrated a higher cellular uptake
than the BPEI-SS-PEG-GE11 (or bGE11) polyplex. These results
suggested that GE11 and bGE11 peptides enhance the cellular
uptake of polyplexes by receptor-mediated endocytosis and the
higher aﬃnity of bGE11 for EGFR facilitates the higher trans-
fection eﬃciency compared to the GE11 tethered polyplex.
In vivo fluorescence bio-imaging and ex vivo biodistribution
Although the targeting eﬃciency of the GE11 and bGE11 pep-
tides tethered to BPEI-SS was successfully investigated in vitro,
these results cannot guarantee the eﬀective clinical eﬃcacy of
the developed polyplexes. Therefore, confirming the targeting
ability of the polyplexes in vivo is a prerequisite for further
clinical application. For in vivo fluorescence imaging, the poly-
mers were labeled with Cy5.5 before complexation with pDNA.
We xenografted EGFR-positive A549 cells to female nude mice.
In vivo experiment was performed when the tumor had
become an appropriate size (∼100 mm3) for imaging. BPEI-S-
S-PEG, BPEI-SS-PEG-GE11 and BPEI-SS-PEG-bGE11 polyplexes
were injected into the tail vein of each nude mouse. 4 h after
injection in vivo fluorescence images were acquired (Fig. 6A).
The non-targeted BPEI-SS-PEG polyplex demonstrated a low
fluorescence signal (yellow) in the tumor. However, the BPEI-S-
S-PEG-GE11 and BPEI-SS-PEG-bGE11 polyplexes showed an
enhanced fluorescence signal at the tumor site compared to
the BPEI-SS-PEG/pDNA polyplex. Especially, the BPEI-SS-PEG-
Fig. 5 FACS histogram. Analysis of EGFR-positive (A) A549 and (B) Huh-
7 cell lines and the EGFR-negative (C) NIH3T3 cell line treated with
YOYO-labeled polyplexes of BPEI-SS-PEG (red), BPEI-SS-PEG-GE11
(green) and BPEI-SS-PEG-bGE11 (blue) at a N/P ratio of 10. 1 × 104 cells
were counted in each sample by FACS.
Fig. 6 In vivo imaging and biodistribution of the polyplexes in tissue
and major organs. (A) In vivo imaging of A549 xenografted mice. Images
were taken 4 h after intravenous injection of Cy5.5 labeled polyplexes.
(B) Quantitative analysis of the relative accumulation in organs retrieved
from the tumor bearing mice 24 h after injection with BPEI-SS-PEG
(red), BPEI-SS-PEG-GE11 (green) and BPEI-SS-PEG-bGE11 (blue) poly-
plexes. The data represent the mean ± SE (n = 3; *P < 0.05, **P < 0.01).
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bGE11 polyplex (red) showed the highest accumulation at the
tumor site, which is consistent with the in vitro transfection
and FACS results.
In this gene delivery system, it is expected that the poly-
plexes should be mainly delivered into the target tumor
without non-specific delivery to the normal organs including
the spleen, lung and kidney, etc. Therefore, the biodistribution
of the polyplexes was evaluated ex vivo to confirm the targeting
ability (Fig. 6B). After 24 h post-injection, all mice were sacri-
ficed and the fluorescence intensity of the major organs was
measured. In the case of BPEI-SS-PEG, the fluorescence inten-
sity of each organ was observed in the order of liver, lung,
kidney, spleen and tumor. In the case of BPEI-SS-PEG-GE11,
the polyplex accumulation was confirmed in the order of liver,
kidney, spleen, lung and tumor. In the case of BPEI-SS-PEG-
bGE11, polyplexes were present in organs in the order of liver,
tumor, kidney, lung and spleen. As expected, the BPEI-SS-PEG-
bGE11/pDNA polyplex showed the highest accumulation of
polyplex at tumor sites. These results clearly indicate that the
bGE11-conjugated polyplex can deliver a gene to the targeted
tumor eﬀectively and reduce non-specific delivery to the
normal organs, showing the potential for use in treatments of
EGFR-overexpressed cancer.
Conclusions
In this study, we have developed an EGFR targeted bioreduci-
ble BPEI for eﬃcient targeted gene delivery. EGFR targeted
BPEI-SS showed eﬃcient gene complexation ability and a suit-
able size and zeta potential for gene delivery in vitro and
in vivo. Compared to non-targeted polymers, GE11- or bGE11-
conjugated BPEI-SS showed enhanced transfection eﬃciency
in vitro and tumor-targeted biodistribution in vivo. In addition,
the bGE11-conjugated polymers showed higher targeting
ability than the GE11-conjugated polymers due to the multi-
valent interaction between ligand and receptor. Taken
together, our results suggest that branched structure of the tar-
geting ligand will be one of strategies used to design eﬃcient
targeted delivery systems.
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